References: to achieve anticancer synergism. ACS Nan., 6,

References:

 

Ahmad, N.A., I.S. Hamdallah and Y.O. Abdallah: Chitosan-coated diacerein nanosuspensions as a platform for enhancing bioavailability and lowering side effects: preparation, characterization and ex-vivo-in vivo evaluation. Int J Nanomed., 12, 4733-4745 (2017).

 

Bhirde, A.A., V. Patel, J. Gavard, G. Zhang, A.A. Sousa, a. Masedunskas, R.D. Leapman, R. Weigert, J.S. Gutkind and J.F. Rusling: Targeted Killing of cancer cells in vivo- invitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano., 24, 307-3023 (2009).

 

Bocci, G., C. Barbara, F. Vannozzi, A. Dipaolo, A. Melosi, G. Barsanti, G. Allegrini, A. Falcone, M. Deltacca and R. Danesi: Apharmacokinetic –based test to prevent severe 5-fluorouracil toxicity. Clin Pharmacol Ther., 80, 384- 395 (2006).

 

Jenning, V., A.F. Thunemann and S.H. Gohla: Characterization of a novel solid lipid nanoparticles carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm. 20, 167-177 (2000).

 

Kumar, D. S. Srivastava and R.K. Dixit: RP-HPLC-PDA method validation for the determination of metformin in bulk and dosage form. World J Pharm and Pharm Sci. 3, 745-757 (2014).

 

Leichman, C.G., K. Chansky, J.S. Macdonald, M.A. Doukas, G.T. Budd and J.L. Abbruzzese: Biochemical modulation of 5-FU through dihydropyrimidine dehydrogenase inhibition- a southwest oncology group phase II trial of eniluracil and 5-FU in advance resistant colorectal cancer. Invest N Drugs., 4, 149-424 (2002).

 

Levin, J. and J. Hohneker: Phase II trial of 5-FU plus eniluracil in patients with advanced pancreatic cancer: a southwest oncology group study. Invest N Drugs., 4, 383-390 (2000).

 

Liu, W., X. Li, Y.S. Wong, W. Zhang, W. Cao and T. Chen: Selenium nanoparticles as carrier of 5-FU to achieve anticancer synergism. ACS Nan., 6, 6578-6591 (2012).

 

Matteucci, M.E., M.A. Hotze, K.P. Johnston and R.O. Williams: Drug nanoparticles by anti-solvent precipitation: mixing energy versus surfactant stabilization. Longmuir, 22, 8951-8959 (2006).

 

Milano, G. and A.L. Chamorey: Clinical pharmacokinetics of 5-FU with consideration of chrono-pharmacokinetics. Chronobiol Int. 1, 177-189 (2002).

 

Nair, L.K., J. Sankar, S.A. Nair and G.S.V. Kumar: Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA. Int Journal of Nanomed. 6, 1685–1697 (2011).

 

Oh, I., K. Lee, H.Y. Kwon, Y.B. Lee, S.C. Shin, C.S. Cho and C.K. Kim: Release of adriamycin from poly (gamma-benzyl-L-glutamate) poly (ethylene oxide) nanoparticles. Int J Pharm., 181, 07-15 (1999).

 

Shadab, M., G. Shalini, F. Sana and S. Saurabh: Nanotechnology as carriers for chemotherapeutics- future of drug delivery. World J Pharm Res., 4, 923-946 (2015).

 

Steven, T.S., M. Sherwood, D. Nichols, R.B. Penne, T. Sery and G. Spaeth: Pharmacokinetics of 5-FU liposomal delivery system. Bri J Opth., 72 688-691 (1998).

 

Yishing, M.Y.I. Ping, T.H. Lin, H.C. Wen, H.J.S. Hang and W.J. Yuan: High glucose modulates anti-proliferative effect and cytotoxicity of 5-FU in human colon cancer cells. DNA Cell Bio., 1, 64-72 (2014).

BACK TO TOP